univers coverag
calendar event
medacorp puls call complic compound resurg
medic meet american academi otolaryngolog head neck surgeri aao-
hnsf american colleg gastroenterolog american colleg chest physician
american rhinolog societi american societi reproduct medicin obsv congress
neurolog surgeon european colleg neuropsychopharmacolog
pleas refer disclosur appendix analyst certif import disclosur price chart
disclosur specif cover compani avail
contact leerink partner editori depart statement valuat risk avail note
follow public contact leerink partner editori depart rx trend deriv im
fine-tun btk autoimmun -- initi op pt
bottom line initi coverag outperform
rate price target compani develop small molecul antibody-lik properti
util uniqu coval bind technolog tunabl degre target engag
optim intend diseas rate valuat base sale forecast
lead asset orphan diseas pemphigu immun thrombocytopenia purpura
itp combin believ reach peak sale risk-adjust
probability-of-success respect bruton tyrosin kinas btk inhibitor
chronic autoimmun diseas phase iib data pemphigu demonstr success
differenti among crowd class date fallen short potenti non-oncolog
indic phase ii data pemphigu set new standard efficaci safeti
toler diseas even though rituxan approach limit market
potenti conveni clinic profil enabl principia captur
meaning market share phase trial start quarter finish
estim compani platform gener multipl catalyst new indic
new target molecul interven period
principia drug design platform optim specif pk/pd small molecul medicin
uniqu profil find immedi nich rituxan-domin pemphigu indic
pipelin catalyst continu
leerink model valu pemphigu itp
split evenli base disclos result
esmo abstract disclos increment safeti data esmo
bottom line abstract european societi medic oncolog esmo poster
present publish even among publish abstract data adap
present abstract indic manag toxic profil dose level
evid on-target off-target toxic patient treat date view safeti
updat abstract increment given adap alreadi dose escal beyond dose
notabl esmo adap also present proprietari tcr program
although late break abstract avail start offici congress session
present manag note safeti data avail
present esmo respons data preliminari
best recal adap clinical-stag biotechnolog compani pioneer develop t-
cell base immunotherapi cancer adap tcr platform could potenti address solid tumor
view transform cell therapi space success adap proprietari platform
enabl gener engin tcr-base cell therapi permit target wide rang
antigen exploit monoclon antibodi chimer antigen receptor -t
view adap leader potenti disrupt tcr field howev also view execut
key adap stori natur consequ adap leadership posit rel new tcr
field develop risk includ time clinic progress due hurdl associ enrol
screen patient involv physician educ discoveri true rate antigen express
clinic vs publish literatur well human leukocyt antigen hla restrict view
potenti import valid year adap tcr platform multipl data readout expect
includ adap proprietari clinic stage tcr program afp
repres key valu driver compani link reiter op
manag toxic cell cohort
catalyst repres key opportun platform valid
littl new data disclos esmo abstract present
bottom line abstract european societi medic oncolog esmo poster
present publish even among publish abstract abstract
on-going phase i/ii forward-ii studi mirvetuximab soravtansin antibody-drug
conjug target folat receptor fr plu keytruda platinum-resist ovarian cancer
data publish today disclos littl new inform investor wait
actual present believ investor expect ahead data low given past
manag guidanc esmo data provid initi read object respons rate orr
may earli meaning data durabl respons progression-fre
surviv also believ investor expect cautiou ahead esmo mirvetuximab
plu keytruda combin orr given high bar compel mirvetuximab monotherapi data
set especi absenc mpf dor durabl respons data howev long-term
continu favor view stock medacorp kol check indic optim
ahead forward-i monotherapi readout kol discuss mirvetuximab ahead multipl
data readout month takeaway oncolog panel addit
forward-ii present esmo forward-i data also expect
updat two next-gen antibody-drug conjug candid
partner op american societi hematolog annual meet
reiter op price target
littl new data esmo abstract
full forward-ii present esmo gen updat next
bottom line catch eye year abstract american societi nephrolog
confer key efficaci data posit read-through rtrx rare kidney
franchis octob interim wk result present open-label extens
ole portion compani duet studi evalu lead asset sparsentan focal
segment glomerular sclerosi npv encouragingli recent publish
abstract indic sustain improv two key surrog marker kidney function
also endpoint accelerated/ful approv on-going duplex trial
reiter op
reduct proteinuria wk continu show promis achiev acceler
endpoint
interim analysi wk posit provid investor longest on-treat effect
second ceo chang last month
bottom line believ new ceo murray kessler consum background
complementari state intent august separ gener busi focu
consum busi howev compani work strateg plan
past sever month previou ceo uwe roehrhoff therefor chang leadership
stage could result delay chang direct initi also put
pressur leadership execut gener side busi also explor
separ sale approach time still determin would expect
pressur news investor look visibl strateg plan
next step gener consum busi
announc appoint murray kessler new ceo effect immedi
bottom line ahead pivot readout rtrx pantothen kinase-associ
neurodegener pkan program npv compani recent present two
poster intern congress parkinson diseas movement disord md
elucid util novel pkan-act daili live adl
score primari endpoint on-going registr fort studi although maintain
po program data report support enthusiasm
demonstr disease-modifi effect fosmetpantoten asset achiev
first-to-mkt statu rare life-threaten diseas reiter op
primer pkan-adl employ pivot fort studi
natl hist studi establish tight align pkan-adl scale pt outcom
poster present outlin on-going pivot fort trial provid clariti studi design
reimburs overnight sinuva still matter
impli ev/sal
bottom line recent check lead on-going aao-hnsf american
academi otolaryngolog confer reinforc view sinuva under-appreci
potenti signific growth acceler driver out-year even though
veloc sinuva adopt could continu gate near-term challeng
reimburs situat check remind convert ent ear nose throat
physician buy bill bnb overnight process entir new territori doctor --
submit drug also believ slower reimbursement-driven ramp alreadi factor
expectations/consensu point forecast achiev sinuva long-
term potenti fulli reflect stock price sinuva risk-adjust dcf impli
pt appli risk-adj sinuva forecast handicap sinuva estim even
say instead risk-adjust dcf analysi suggest valuat
roughli stock current trade us suggest good amount reimbursement/
execut risk alreadi price assum risk adjust sinuva forecast dcf yield
sinuva feedback highlight ent implant sinuva satisfi their/pati
howev feedback also confirm reimburs continu limit veloc pace adopt
nearer-term surprisingli
stock earn j-code decis like occur within day one anoth
think in-lin would consid win -- especi j-code goe xent way
event requir re-submit j-code applic j-code decis
go compani way nov stock downsid potenti could mitig
regard potenti monoclon antibodi dupilumab treatment nasal polyposi ent
seem think derail sinuva adopt and/or
in-licens pomp fabri gene trx expect detail day
bottom line expect link amicu tackl investor long-stand concern
surround fabri pomp franchis in-licens gene therapi candid
univers pennsylvania importantli partner promin gene therapi leader
like jame wilson wilson lab signific leverag advantag go forward
boost compani odd success marri wilson gene therapi expertis
biolog expertis although stock risen sinc recent investor dinner
believ today announc supplement investor sentiment head
analyst day octob investor expect addit detail reiter op
well get agil value-bas agilon health
bottom line march toward value-bas care vbc continu wellcar ink
partnership agilon health today provid member texa access provid
vbc arrang member wellcar one largest mco focus
exclus government-sponsor plan continu partner innov compani focus
vbc agilon health believ wellcar continu differenti competit
medicar advantag manag medicaid market recal push aggress move
vbc medicar goal tie payment vbc medicaid histor
focus vbc begun catch wellcar note vbc increasingli becom score
compon requir medicaid rfp wellcar medicar medicaid
payment current vbc arrang respect
outlook uncertain near-term execut long-term technolog lead
biopharma financ wide window new issu
 loxo updat ata reaffirm ret activ
razor blade instrument placement fear overblown
believ investor expect head ph data readout
low especi sinc lack clariti around requir approv
still discuss fda around data analysi plan studi link
niemann-pick type np-c ultra-rar progress neurodegen genet
diseas occur bodi properli break cholesterol lipid
lead harm amount lipid accumul spleen liver brain
believ ph i/ii result encourag given breakthrough
statu drug fda prior comment bar approv like low
medacorp specialist spoke enthusiast current
treatment altern off-label use miglustat limit efficaci high ae
rate diarrhea abdomin pain nausea
forecast sale grow larg opportun
believ one sever pipelin asset critic offset
declin key franchis acthar inomax ofirmev face competit
come year posit regulatori execut increas investor
interest emerg pipelin
discuss around approv prospect gener advair posit earn
manag indic complet respons letter june includ minor
label chemistri manufactur control relat question
submit respons mid-juli standard three month goal date
although hope sinc product prioriti design approv could come
manag emphas addit data requir part respons
remain readi launch upon approv
clovi present data rubraca phase studi poster
discuss session esmo cest edt
trial evalu rubraca monotherapi refractory/relaps metastat castrat
resist prostat cancer mcrpc patient fail prior next-gener
androgen receptor target therapi one line taxan base chemo
dataset expect includ patient roughli brca patient
brca patient expect evalu recist respons
focu expect recist respons rate data regulatori
endpoint need consider acceler approv note receiv
breakthrough therapi design base data suggest data
esmo like compel link recent note
trial lead approv prostat cancer rubraca could first parp gain
indic link initi
indic compani could file acceler approv prostat
cancer base data
esmo adap present initi efficaci data t-cell receptor tcr
program multipl solid tumor type urotheli melanoma head neck ovarian nsclc
adap clinical-stag biotechnolog compani pioneer develop t-
cell base immunotherapi cancer
compani tcr platform could potenti address solid tumor view
transform cell therapi space success
adap proprietari platform enabl gener engin tcr-base cell therapi
permit target wide rang antigen exploit monoclon
antibodi chimer antigen receptor -t
project probability-weight nsclc scchn bladder sale
expect potenti signific stock price reaction presentaton
initi ph i/ii efficaci data tcr studi non-smal
cell lung cancer nsclc tripl tumor studi
present phase ii data tazemetostat epithelioid sarcoma es also
ini tumor cohort
initi approv tazemetostat could es drug demonstr
respons rate diseas control rate rare sarcoma littl
updat data expect esmo compani expect present durat
respons data key fda assssment respons rate data
regulatori file expect mild delay origin guidanc
compani resolv partial clinic hold
es small indic modest fundament valu peak us revenu
risk-adjust npv probabl success approv could
help de-risk larger opportun especi light recent partial clinic hold
potenti safeti regulatori concern link
imgn lead proprietari product candid mirvetuximab soravtansin current phase
develop forward-i single-ag platinum-resist ovarian cancer
addit on-going forward-ii phase i/ii studi evalu drug
combin avastin keytruda carboplatin avastin tripl studi advanced/
present data forward-ii avastin combin american societi
clinic oncolog respons rate substanti improv
mirvetuximab monotherapi mark improv progression-fre
surviv durat respons
plan present addit phase ii expans data patient treat
medium high fr-alpha express part keytruda combin
medacorp kol spoken express mix view combin
especi combin keytruda given limit success ovarian cancer
oct dupix asthma indic pdufa
expect dupix sbla approv asthma adult/adolesc patient
consid import catalyst stock
subgroup eosinophil asthma patient dupix confer
exacerb reduct benefit greater lung function benefit approv
-- market drug class eosinophil asthma
believ total product consensu revenu expect surpass
revenu contribut eosinophil asthma patient
given data prefer partner sni focu data label effort
eosinophil patient order highlight superior medicin
full analysi refer note dupi asthma estim dont reflect superior
vs eosinophil asthma outperform
like provid addit detail around launch prepar nyzyra
manag may also releas price detail nuzyra omadacyclin acut bacteri
skin skin structur infect abssi commun acquir bacteri pneumonia
capb well date launch
model roughli iv oral indic
continu see nuzyra grow sale
recent note addit thought nuzyra approv rais pt
tx award expect announc octob effect date
new contract expect januari
current oper region tx estim market share
submit bid region compani remain posit around retent
least exist tx region
reprocur could mean mm revenu beneficiari
call announc earlier-than-expect complet enrol
follow-up stemi short-term elev myocardi infarct feasibl studi
put data present like aha chicago pivot trial start
possibl earli time-frame sooner base estim
esposito et al publish result anim studi jacc support left
ventricular unload prior reperfus translat human would impli impella
success stemi reduc infarct size prevent late-stag onset
heart failur -- someth would clinic relev also cost effect
concurr editori jacc review clearli bullish implic
esposito studi potenti impella use stemi patient outcom
reproduc human primari mechan lv unload enorm benefit
reduc futur hf event patient acut mi note intervent cardiologist
may also need prepar modifi therapeut strategi mi
estim stemi year would
doubl exist address patient popul high risk pci cardiogen
compani develop varlitinib indic high preval asia includ
biliari tract cancer gastric cancer
asln expect multipl data readout includ
interim readout phase i/ii studi varlitinib gemcitabin cisplatin line
top-lin data global phase ii/iii studi varlitinib folfox co-
interim data ph ii studi dhodh inhibitor acut myeloid leukemia
believ data present american psychiatr associ confer
provid limit insight genesight endpoint
view test key mygn long-term top-lin growth potenti
drive revenu upsid reimburs mygn desir
current medicar rate
signific controversi alreadi surround reach potenti given
pt trial fail meet primari endpoint met secondari endpoint remiss
respons data may provid sub-
analysi patient fail chang view medacorp specialist payer
journal public expect june coverage/contract decis expect
announc beyond
link takeaway meet manag
regulatori settlement behavior health feder state agenc appear like
posit catalyst
negoti remain on-going manag optimist settlement reach
investig state feder regul year
settlement reserv increas pre-tax
given superl clinic data present date expect fda approv
nov link note
larotrectinib loxo lead agent potent specif pan-trk tropomyosin receptor
kinas inhibitor combat basket tumor includ lung breast colon
trk biomark individu estim us
larotrectinib next-gen trk inhibitor partner bayer hold
ex-u commerci right pay loxo tier double-digit royalti ex-u sale
loxo bayer co-develop us cost profit split loxo
receiv up-front payment potenti receiv mileston payment
us ou larotrectinib
project combin larotrectinib peak probability-of-success
adjust sale us europ larotrectinib eu
submit august
esmo loxo updat larotrectinib trk-driven cancer nda
dataset inform drug develop durabl toler
year addit matur dataset
dec epo patent challeng relat rubraca ovarian prostat
dec european patent offic epo hear oral argument render
opinion patent challeng camsyl salt patent provid ip protect
eu drug rubraca
challeng file divis sandoz anonym parti contend
epo patent recent grant clovi novel -- argument preliminari
opinion agre cite prior art exist applic file
medacorp specialist review preliminari opinion render april felt
opposit strong argument could result narrow patent claim
claim narrow eu could make invent step difficult
uphold unexpect product attribut may compar broadli potenti
open door prior art consid
view eu patent challeng relev impact potenti
takeout option potenti read-through us exclus
composit matter patent expir without addit patent support drug
intellectu properti ip runway relev us patent howev like
hotli debat even dec goe poorli
outcom difficult predict epo opinion could appeal either
parti like believ signific event share --
unfavor opinion could lower valuat definit favor
opinion could rais
present initi rubraca data prostat cancer esmo oct
sourc leerink research compani inform factset price prior day
fda adcom anesthet analges drug product
fda adcom joint gastrointestin drug drug safeti risk
pdufa dupix moder sever asthma adult adolesc
fda adcom scienc board fda
fda adcom endocrinolog metabol drug
fda adcom joint psychopharmacolog drug drug safeti risk
fda adcom vaccin relat biolog product
pdufa revefenacin lama copd
fda adcom anesthet analges drug product roxicodon
pdufa roxicodon abuse-deterr formul immediate-releas single-
epo decis ip tsro
pdufa bremelanotid hypoact sexual desir disord fda adcom
schedul
american colleg gastroenterolog
american colleg chest physician
european colleg neuropsychopharmacolog
congress neurolog surgeon
american societi reproduct medicin obsv
american academi otolaryngolog head neck surgeri aao-hnsf annual
american committe treatment research multipl sclerosi
intern societi technolog arthroplasti
american societi dermatolog surgeri
european associ neuro-oncolog
american associ blood bank
american societi anesthesiologist
european associ nuclear medicin
european societi gene cell therapi
american societi human genet arql
american colleg dentist
european associ cardiothorac surgeri
european societi medic oncolog adap asln
american colleg rheumatolog
canadian associ pediatr health centr
colleg american pathologist
american societi therapeut radiolog oncolog
american academi child adolesc psychiatri
american societi nephrolog kidney week
clinic trial alzheim diseas
american academi physic medicin rehabilit
american academi ophthalmolog
american academi periodontolog
american colleg prosthodontist
associ molecular patholog
american associ scienc
societi immunotherapi cancer
intern confer societi medic innov technolog
intern societi traumat stress studi
american associ studi liver diseas
model model recent updat pleas contact leerink
repres wish review
 takeaway immuno-oncolog panel
 takeaway nash panel
biopharma lp hic takeaway ibd panel
 takeaway migrain panel
biopharma lp hic reimburs panel oncolog gene therapi target limit
 rova-t present show anoth rout failur experiment oncolog
adap -- flash manag convers highlight data pipelin progress
adap studi advanc cell dose posit safeti data pt
-- flash present highlight opportun colorect cancer
celg updat strengthen profil remark respons durabl
celg profil continu present outperform
 tazemetostat mesothelioma data opportun combin outperform
 success pamrevlumab lapc may depend endpoint paradigm shift
imdz -- flash event highlight imdz approach strategi outperform
 event highlight investig view forward ii data outperform
-- flash highlight encourag data biomark strategi gastric
-- flash updat demonstr continu safeti earli efficaci
 west coast alzheim kol provid discourag view amyloid aaic
 half full half empti alzheim diseas puls call takeaway market perform
biopharma price pledg made biopharma what happen
biopharma biopharma catalyst tracker import catalyst remain second half
 takeaway annual day
 biotech portfolio concentr explain multipl compress
 first apprais tax offer small benefit
 vertex alexion top pick
biopharma novel pain treatment class bar far limit potenti
-- flash takeaway leerink day outperform
 eas data confirm durabl gocovri superior vs gener
 day preview late stage program turn launch mani
 takeaway annual day
-- flash takeaway leerink day outperform
-- flash takeaway leerink day outperform
-- flash takeaway leerink day outperform
-- flash takeaway leerink day outperform
 growth deal capac target market
biopharma praluent show mortal benefit lower take aim highest risk group
mdco kol see distinct pt address vascepa reiter greater need
novob dc highlight nvo management roundtabl discuss boston market
 glucagon rescu progress schedul outperform
medic devic ada dash make splash highlight recent
medic devic leerink healthcar confer panel devic penetr set
medic devic leerink leadership seri outset drive shift dialysi self-car
medic suppli devic la med-tech day deep dive physician view
medic devices-cardiolog hr takeaway cabana unlik chang af practic
medic devic survey support market share re-gain assumpt
medic suppli devic initi takeaway sage robot continu gain
medic devic leerink healthcar confer panel devic penetr set
biopharma price pledg made biopharma what happen
biopharma price right payer fail get drug class come
 stabil sell-sid price trend medic posit ug op outperform
 acthar survey suggest faster eros payer pressur competitor entri
qure updat model higher price assumpt po pt
 price commerci updat fda approv burosumab/crysvita
 respit price yet friendli hill fda could
biopharma trump-azar puls call drug price blueprint limit current hh
 hemophilia price adjust reflect efficaci luxturna paradigm pt
 outlook move higher price clariti suggest possibl upsid pt
hcit distribut blueprint thorough pbm like abl manag rebat
hcit distribut outlin possibl drug price polici draconian
fear
 updat hemophilia price assumpt ad pomp program pt
biopharma futur ibd categori doubl despit
biopharma ibd inflamm market grow
brand ibd medicin grow rais est
celg dose-respons plenti evid activ otezla uc outperform
celg qed ged late stage failur throw ibd bd strategi
celg ozanimod worth rang rrm ibd result outperform
ibd kol call market face disrupt jak displac tnf
uegw highlight fierc competit ibd clear-cut winner
 patent strategi come focu mitig biosimilar risk outpfrm outperform
 news patent decis one remind method use patent
 doubl extend patent horizon tecfidera
 investor sleep path ip protect pt
adap kol address controversi ahead multipl data readout outperform
 anoth setback ido outperform ideal combo still unclear
biopharma what immuno-oncolog takeaway
biopharma summari leerink immuno-oncolog roundtabl
celg anoth bet car-t probabl probabl sensibl even
 deep dive highlight oncolog focu strategi nash market perform
 highlight kol panel lung cancer io cell
celg anoth bet car-t probabl probabl sensibl even
biopharma might deton event look like screen pot match-
 sotp support current stock price where pipelin upsid market
 sotp suggest pipelin free even stock bounc market perform
 dupi miss-inventori demand trend intact partnership flail
biopharma viii partnership acquisit biopharma new top list
ci june ci cfo boston meet insight rais pt outperform
 aet bring comprehens member
dplo mid-mkt pbm acquisit complet strateg move market perform
esrx detail esrx deal term dplo may acquisit target
 evolv provid landscap initi outperform initi
outperform
 partnership valid local jaki gut de-risk develop path pt
 increas pt takeda collabor stock weak offer oppti
manag -- flash gov lose t-twx close without condit posit
pharmaci benefit manag t-twx approv bode pend ci-esrx cvs-
outperform
outperform
perform
outperform
initi coverag target oncolog
perform
outperform
 research micro-dystrophin
-- contact leerink repres detail access podcast
 pnh survey-soliri still grow like switch monthli sc best
athn survey highlight slow market time take deal pt market
 cll survey suggest signific opp next-gen btk improv
 medacorp payor survey highlight favor statu quo intact orphan
hcit distribut ambulatori survey show slowdown replac market on-going
shift vbc
 medacorp survey highlight driver headwind ali pt outperform
 awak w/ solriamfetol rais est follow medacorp survey pt
major medacorp survey lung cancer posit azn
medic devices-cardiolog tavr survey in-lin out-year trend quarter look
ew thv link link
medic suppli devic survey suggest may wait
medic devic survey support market share re-gain assumpt
 acthar survey suggest faster eros payer pressur competitor entri
 bone pick medacorp survey suggest solid crysvita adopt esp
 survey confirm bullish view adcetri frontlin hl reiter op pt
teva rais austedo sale analysi posit medacorp physician survey
 leadership seri growth momentum sustain stemi data catalyst
 open ablat atriclip drive near term growth mi longer term
 leadership seri call highlight upsid potenti neuromodul outperform
 leadership seri busi sourc lt upsid outperform
 differenti poc signific runway impli upsid pt
 leadership seri growth acceler strong gener outperform
 ceo call focus growth outlook potenti upsid area lrp pt
outlook alpha opportun abound healthcar share
